Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Neoadjuvant Therapy in Resectable NSCLC
NCT05577702Phase 2Completed
- Sponsor
- BeiGene
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by BeiGene. Primary endpoint: Major Pathological Response Rate at Week 16. Started Mar 2023; status: completed.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05577702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05577702.